Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact... IntroductionBiosimilars are biological medicines that are highly similar to the originator product. Availability of biosimilars for biological products which go off patent is expected to decrease per‐patient treatment costs and provide greater patient access, contributing to the reduction in disability, morbidity and mortality associated with inflammatory diseases.There are well‐defined regulatory guidelines in the United States (US) and the European Union (EU) on scientific considerations for demonstration of biosimilarity; the EU guidelines are considered the gold standard for authorization of biosimilar medicines. From the perspective of interchangeability between an originator and a biosimilar, the US Food and Drug Administration (US FDA) has recently issued a draft guidance on considerations in demonstrating interchangeability of a biosimilar with a reference product (originator). In the EU, there is no separate designation of interchangeability, rather biosimilars can be viewed as interchangeable, and the decision is left to individual member states for framing the rules. Apart from the regulatory perspective, the evaluation of the effect of multiple switches between originator and biosimilar with regard to efficacy, safety and immunogenicity is of great interest to physicians and patients.GP2015 (Erelzi™) is an etanercept biosimilar approved by the US FDA for treatment of rheumatoid arthritis and polyarticular juvenile http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study

Loading next page...
 
/lp/wiley/multiple-switches-between-gp2015-an-etanercept-biosimilar-with-8D0cL5fac4
Publisher
Wiley
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
D.O.I.
10.1111/jdv.14605
Publisher site
See Article on Publisher Site

Abstract

IntroductionBiosimilars are biological medicines that are highly similar to the originator product. Availability of biosimilars for biological products which go off patent is expected to decrease per‐patient treatment costs and provide greater patient access, contributing to the reduction in disability, morbidity and mortality associated with inflammatory diseases.There are well‐defined regulatory guidelines in the United States (US) and the European Union (EU) on scientific considerations for demonstration of biosimilarity; the EU guidelines are considered the gold standard for authorization of biosimilar medicines. From the perspective of interchangeability between an originator and a biosimilar, the US Food and Drug Administration (US FDA) has recently issued a draft guidance on considerations in demonstrating interchangeability of a biosimilar with a reference product (originator). In the EU, there is no separate designation of interchangeability, rather biosimilars can be viewed as interchangeable, and the decision is left to individual member states for framing the rules. Apart from the regulatory perspective, the evaluation of the effect of multiple switches between originator and biosimilar with regard to efficacy, safety and immunogenicity is of great interest to physicians and patients.GP2015 (Erelzi™) is an etanercept biosimilar approved by the US FDA for treatment of rheumatoid arthritis and polyarticular juvenile

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off